• 05/06/2016 Talcum Powder- Ovarian Cancer Lawsuit Helpline: Talcum Powder- Ovarian Cancer Lawsuit? Talcum Powder lawyers for   Allentown, Erie, Harrisburg, Lancaster, Meadville, Philadelphia, Pittsburgh, Pocanos, Reading, Scranton, Williamsport, women  who now have an ovarian cancer diagnosis from ...
  • 05/06/2016 Florida Talcum Powder Ovarian Cancer Lawyers: Florida Talcum Powder- Ovarian Cancer  Lawyers Get a Baby Powder and Shower- Shower lawyer to  file a ovarian cancer  lawsuit if   your ovarian cancer can be  linked to using talcum powder. It is now known that talcum powder can cause a si...

Posts Tagged ‘PE’

Yaz lawyers Arkansas Filing lawsuits for yaz Pulmonary Embolism, blood clots

Written by lisaspitzer on . Posted in Arkansas Yaz Lawsuit

Yaz Birth control pills lawyers Arkansas filing yaz lawsuits for Blood clots, Pulmonary embolism, stroke, hear attack from yaz for women in Fayetteville, Fort Smith, Jonesboro, Little Rock and all of Arkansas.

If you have a daughter injured by the birth control pill Yaz  call  the yaz Birth control pills helpline Arizona and speak to our female Yaz counselor. We will help you locate a yaz lawyer. Young women have taken Yaz birth control pills and many have had severe complications. Bayer has started the Yaz Birth control pills settlement  process. The FDA has added additional warnings for Yaz Birth Control pills. Now is the time to speak to a Yaz lawyer if your daughter was injured by Yaz. Complications include stroke, Blood clots, deep vein thrombosis and pulmonary embolism. Yaz has caused serious complications that have injured many young women and has caused deaths.

The new FDA warnings will apply to all birth control pills that contain the synthetic hormone drospirenone, which many experts think is the culprit which causes so many Yaz side effects. Drospirenone is found in Yaz, Yasmin, Beyaz, and Safyral birth control. Call us and get the Yaz birth control facts today. Yaz lawyers are filing yaz lawsuits for Wrongful Death from yaz Birth control pills.

Yaz can Cause

  • Deep vein thrombosis ,(DVT).
  • Pulmonary embolism ,(PE),
  • Heart attack,
  • Stroke,
  • Death,

Bayer has started payouts for yaz. Get a yaz lawyer from the yaz birth Control pills helpline today.


Yasmin Warnings for Blood Clots, Yasmin Lawsuits for Blood Clots

Written by lisaspitzer on . Posted in Yaz Helpline News

Federal health regulators said Tuesday they are adding labeling to Yaz and other newer birth control pills emphasizing that the drugs may be more likely to cause blood clots than older contraceptive pills. Yaz Birth Contro Pills Helpline and Yasmin Lawyers are filing lawsuits for blood clots from Yasmin.

The labeling will apply to Bayer's Yaz, its predecessor Yasmin and similar drugs containing the manmade hormone called drospirenone, which mimics the naturally occurring female hormone progesterone. The drugs are among the best-selling contraceptives in the U.S., due to marketing emphasizing their ability to clear up acne and other hormone-related issues.

The FDA said the new labeling will detail recent studies suggesting drospirenone-containing pills carry a slightly higher risk of blood clots than other birth control pills. The risk of blood clots with either group of drugs is still very rare. If you or a daughter has a severe debilitating injury related to Yasmin blood clots contact the Yaz Helpline today and speak to a Yasmin lawyer



Bayer A History, And Today Lawyers Sueing Bayer for Yaz Birth Control Pills

Written by lisaspitzer on . Posted in Yaz Helpline News

Now in May of 2012  settlements  have begun by lawyers suing Bayer Pharmaceuticals  for  women who have had serious complications due to blood clots from Yaz. Who is Bayer and what is their history

Who is Bayer Pharmaceuticals  and what is their history ?

Bayer AG is a chemical and pharmaceutical giant founded in Barmen, Germany in 1863 by Friedrich Bayer and his partner, Johann Friedrich Weskott. Today it has its headquarters in Leverkusen, North Rhine-Westphalia, Germany. It trademarked acetylsalicylic acid as aspirin in 1899. It also trademarked heroin a year earlier, then marketed it world-wide for decades as a cough medicine for children "without side-effects", despite the well known dangers of addiction.

During the First World War, Bayer turned its attention to the manufacture of chemical weapons including chlorine gas, which was used to horrendous effect in the trenches. It also built up a "School for Chemical Warfare". During this time Bayer formed a close relationship with other German chemical firms, including BASF and Hoechst. This relationship was formalised in 1925 when Bayer was one of the chemical companies that merged to form the massive German conglomerate Interessengemeinschaft Farben or IG Farben, for short. It was the largest single company in Germany and it became the single largest donor to Hitler's election campaign. After Hitler came to power, IG Farben worked in close collaboration with the Nazis, becoming the largest profiteer from the Second World War. Amongst much else, IG Farben produced all the explosives for the German military and systematically looted the chemical industries of occupied Europe. It's been described as the Nazis' "industrial jackal" following in the wake of Hitler's armies.

During the Second World War, IG Farben used slave labour in many of its factories and mines and by 1944 more than 83,000 forced labourers and death camp inmates had been put to work in the IG Farben camp at Auschwitz in Nazi-occupied Poland. Auschwitz was a vast labour and death camp where more human beings were put to death than were killed in the whole of World War I. It was comprised by 3 main camps: Auschwitz I, a concentration camp; Auschwitz II (Birkenau), an extermination camp in which by 1944 some 6,000 people a day were being killed; and Auschwitz III, which supplied slave labour for the nearby IG Farben plant (Buna-Werke, also known as IG Auschwitz).

IG Farben's Auschwitz plant was a massive industrial complex. The largest outside of Germany, it consumed as much electricity as the entire city of Berlin. Built and run by slave labour, it is thought – at a conservative estimate – to have cost at least 35,000 lives. In 1941, Otto Armbrust, the IG Farben board member responsible for IG Farben's Auschwitz project, told his colleagues, "our new friendship with the SS is a blessing. We have determined all measures integrating the concentration camps to benefit our company." But not only did thousands of slave labourers die from the conditions in which they worked for IG Farben, those camp inmates who were viewed as too sick or weak to continue to labour in the IG Auschwitz plant were selected for the gas chambers. IG Farben paid 100,000 reichsmarks each year to the SS and in return was assured a continuous supply of fresh slave labour, while being "relieved" of unfit inmates.

Elie Wiesel, the writer, Nobel Laureate and Holocaust survivor, came to Auschwitz in 1944 and was sent with his father to IG Farben's Buna work camp. That same year, the Holocaust survivor and author Primo Levi was among 125 men selected at the railhead for labour at IG's Buna-Werke. One of only 3 survivors from this group, Levi later wrote about his experiences in searing detail: "A fortnight after my arrival there I already had the prescribed hunger, that chronic hunger unknown to free men… On the back of my feet I already have those numb sores that will not heal. I push wagons, I work with a shovel, I turn rotten in the rain, I shiver in the wind, already my own body is no longer mine: my belly is swollen, my limbs emaciated." In Night, Elie Wiesel's acclaimed memoir of his personal experiences of the Holocaust, he describes how veterans of IG's Buna-Werke told those who had arrived there late in the war that the brutal treatment they were experiencing was as nothing to what had previously been endured by the IG work force: "No water, no blankets, less soup and bread. At night we slept almost naked and the temperature was 30 below. We were collecting corpses by the hundreds every day… Work was very hard… [The gangmasters] had orders to kill a certain number of prisoners every day; and every week selection [for the gas chambers] – a merciless selection."

When it came to "selection", it was an IG Farben subsidiary, with IG Farben managers on its Management Committee, that manufactured and supplied Zyklon B to the SS. This poisonous cyanide-based pesticide, on which IG Farben held the patent, was used during the Holocaust to annihilate more than a million people at both the Auschwitz-Birkenau and Majdanek extermination camps. The form of Zyklon B used in the gas chambers was deliberately made without the normal warning odorant. IG Farben also supplied the SS with the Methanol used to burn the corpses.

In 1946 the Nuremberg War Crimes Tribunal concluded that without IG Farben the Second World War would simply not have been possible. The Chief Prosecutor, Telford Taylor, warned: "These companies, not the lunatic Nazi fanatics, are the main war criminals. If the guilt of these criminals is not brought to daylight and if they are not punished, they will pose a much greater threat to the future peace of the world than Hitler if he were still alive." Their indictment stated that due to the activities of IG Farben "the life and happiness of all peoples in the world were adversely affected." Charges as grave as fomenting war and killing slave labourers were also added. In his opening statement the Nuremberg Chief Prosecutor pointed out that, "The indictment accuses these men of major responsibility for visiting upon mankind the most searing and catastrophic war in human history. It accuses them of wholesale enslavement, plunder and murder."

According to the Nuremberg prosecutors, "We have seen Farben integrating itself with the Nazi tyranny, turning its technical genius to the furnishing of… commodities vital to the reconstruction of the German war machine, and emerging in Hermann Goering's entourage at the highest level of economic planning and mobilization for war. We have seen Farben poised for the kill, and subsequently swollen by economic conquest in the helpless occupied countries. Faced with a shortage of workers, we have seen Farben turn to Goering and Himmler, and persuading these worthies to marshal the legions of concentration-camp inmates as tools of the Farben war machine. We have seen these wretched workers dying by the thousands, some on the Farben construction site, many more in the Auschwitz gas chambers after Farben had drained the vitality from their miserable bodies… Literally millions of people were put to death in the very backyard of one of Farben's pet projects – a project in which Farben invested 600 million reichsmarks of its own money."

Although the Nuremberg Tribunal indicted 24 IG Farben board members and executives on the basis of crimes against humanity, only 13 received prison sentences. And the sentences they received were described by the Nuremberg Chief Prosecutor as "light enough to please a chicken thief". By the early 1950s a number of those convicted of slavery, looting and mass murder were back at the helm of the very companies – Bayer, Hoechst and BASF, formed out of the assets of IG Farben in 1952. The owners of these "new" companies were also the shareholders of IG Farben. Thus, although the gravity of the crimes committed by IG Farben meant the company was considered too corrupt to be allowed to continue to exist, it was supplanted by its key constituents – companies like Bayer which were owned, and directed at the highest level, by the very same people as IG Farben. Those who had helped Hitler to power and provided the technical know-how for his wars of aggression and the Holocaust, were back in control of the industry.

The Bayer executive Fritz ter Meer typifies the bounce back. An executive of IG for many years, the most senior scientist on its supervisory board and the chairman of its technical committee, he had become a Nazi Party member in 1937 and was the executive responsible for the construction of the IG Farben factory in Auschwitz, in which tens of thousands of slave labourers met their deaths. Ter Meer's own visits to Auschwitz and the detailed reports he received made it inconceivable that he did not have a clear picture of what was occurring. The Nuremberg War Crimes Tribunal found him guilty of plunder, slavery and mass murder. As a result, Ter Meer received the longest sentence of any of the IG Farben board members. But despite being found the most culpable of the men who, in the words of Chief Prosecutor, "made war possible… the magicians who made the fantasies of Mein Kampf come true", ter Meer was already out of prison by 1952. By 1956 he had become the chairman of the supervisory board of Bayer, a post he held until 1964. Even today Bayer continues to honour this convicted mass murderer. On All Saints Day 2006, for instance, the corporation is known to have laid a wreath on ter Meer's grave in Krefeld-Uerdingen, Germany. Yet for decades Bayer refused to pay compensation to its surviving slave labourers. Only after international protests did it eventually agree to pay damages – more than 50 years after the end of the war.

Bayer continued to grow in the post-war period, eventually becoming bigger than the whole of IG Farben even at its zenith. Even as part of IG Farben, Bayer had maintained its strength in pharmaceuticals. In fact, scientific experiments had been done specifically on behalf of Bayer in Auschwitz and other concentration camps. IG had footed the bill for the research of Josef Mengele, Auschwitz-Birkenau's infamous "Angel of Death", and some of his experiments utilised germs and pharmaceuticals provided by Bayer. Wilhelm Mann, whose father had headed Bayer's pharmaceutical department, wrote as head of IG's powerful pharmaceutical committee to an SS contact at Auschwitz: "I have enclosed the first cheque. Dr Mengele's experiments should, as we both agreed, be pursued. Heil Hitler." IG employee SS major Dr Helmuth Vetter, stationed at Auschwitz, participated in human medical experiments by order of Bayer. Prisoners died as a result of many of these experiments. Vetter was convicted of war crimes in 1947 and was executed in 1949 but Bayer's role only emerged later. In the Auschwitz files correspondence was discovered between the camp commander and Bayer. It dealt with the sale of 150 female prisoners for experimental purposes and involved haggling over the price. One exchange notes: "The experiments were performed. All test persons died. We will contact you shortly about a new shipment at the same price." According to testimony by SS physician Dr Hoven during the Nuremberg War Crimes Tribunal: "It should be generally known, and especially in German scientific circles, that the SS did not have notable scientists at its disposal. It is clear that the experiments in the concentration camps with IG preparations only took place in the interests of the IG, which strived by all means to determine the effectiveness of these preparations. They let the SS deal with the – shall I say – dirty work in the concentration camps. It was not the IG's intention to bring any of this out in the open, but rather to put up a smoke screen around the experiments so that… they could keep any profits to themselves. Not the SS but the IG took the initiative for the concentration camp experiments.

In the post-war years Bayer grew to become the third largest pharmaceutical company in the world. In the mid-1980s Bayer was one of the companies which sold a product called Factor VIII concentrate to treat haemophilia. Factor VIII turned out to be infected with HIV and in the U.S. alone, it infected thousands of haemophiliacs, many of whom died in one of the worst drug-related medical disasters ever. But it was only in 2003 that the New York Times revealed that Bayer had continued producing and selling this infected product to Asia and Latin America after February 1984 when a safe product had become available, in order to save money. Dr. Sidney M. Wolfe, who investigated the scandal, commented, "These are the most incriminating internal pharmaceutical industry documents I have ever seen."

In the early 1990's Bayer is said to have placed patients at risk of potentially fatal infections by failing to disclose crucial safety information during a trial of the antibiotic Ciproxin. Up to 650 people underwent surgery using Ciproxin without doctors being informed that studies (as early as 1989) showed Ciproxin reacted badly with other drugs, seriously impairing its ability to kill bacteria.

In 2001 Bayer had to recall its anti-cholesterol drug Baycol/Lipobay, which was subsequently linked to over 100 deaths and 1,600 injuries. Germany's health minister accused Bayer of sitting on research documenting Baycol's lethal side-effects for nearly two months before the government in Berlin was informed.

It is thought to have been partly in response to the impact of the Baycol scandal that Bayer bought the rival crop sciences unit of French company Aventis, which had absorbed part of Hoechst, in October 2001. Bayer CropScience was formed in 2002 when Bayer AG acquired Aventis CropScience and fused it with their own agrochemicals division (Bayer Pflanzenschutz or "Crop Protection"). The Belgian biotech company Plant Genetic Systems, also became part of Bayer via the acquisition of Aventis CropScience.

Today Bayer CropScience is one of Bayer's core business divisions, which include:

  • Bayer HealthCare: drugs, medical devices and diagnotic equipment;
  • Bayer MaterialScience AG: polymers and plastics;
  • Bayer CropScience: GM crops and agro-chemicals.

Bayer is the world's leading pesticide manufacturer and the world's seventh largest seed company. Bayer CropScience is responsible for the majority of GM field trials in European countries. Bayer's GM crops are mostly "Liberty Link" – designed to be resistant to its "Liberty" herbicide. Liberty is a trade name for Bayer's glufosinate weedkiller. Together with Monsanto's Roundup Ready crops, Bayer's Liberty Link crops are one of the two main types of GM herbicide resistant crops, but glufosinate is a controversial herbicide. In January 2009, the European Parliament voted to ban pesticides classified as carcinogenic, mutagenic or toxic to reproduction. As a result the permit for glufosinate will not be renewed. A European Food Safety Authority (EFSA) evaluation states that glufosinate poses a high risk to mammals. It is classified as reprotoxic, because of research evidence that it can cause premature birth, intra-uterine death and abortions in rats. Japanese studies show that the substance can also hamper the development and activity of the human brain. Bayer's systemic insecticide Imidacloprid, sold in some countries under the name Gaucho, and Clothianidin, have also proven highly controversial as they are widely believed to have contributed significantly to bee deaths. There have been calls for these neonicotinoids to be withdrawn as seed dressings for crops that might affect bees, or even for a complete ban on their use. In May 2008 German authorities blamed Clothianidin for the deaths of millions of honeybees, and the German Federal Office of Consumer Protection and Food Safety (BVL) suspended the registration for eight pesticide seed treatment products, including Clothianidin and Imidacloprid, on maize and rape.

In 2008, Bayer CropScience was at the centre of a huge controversy in the aftermath of an explosion at one of its U.S. pesticide production facilities. A U.S. Congressional investigation found faulty safety systems, significant shortcomings with the emergency procedures and a lack of employee training had led to the explosion which killed two employees. The region apparently narrowly escaped a catastrophe that could have surpassed the 1984 Bhopal disaster. According to the Congressional investigation: "Evidence obtained by the committee demonstrates that Bayer engaged in a campaign of secrecy by withholding critical information from local, county and state emergency responders; by restricting the use of information provided to federal investigators; by undermining news outlets and citizen groups concerned about the dangers posed by Bayer's activities; and by providing inaccurate and misleading information to the public." Bayer CropScience were found to have deliberately removed and destroyed evidence after the chemical explosion.

Bayer CropScience has been involved in a large number of controversies related to GM crops, perhaps most notably the contamination in 2006 of much of the US long-grain rice supply by Bayer's unapproved Liberty Link GM rice. This caused the U.S. rice industry's worst ever crisis with:

over 40% of US rice exports negatively affected

  • multiple federal lawsuits filed
  • trade with the 25-nation EU at a standstill
  • other countries banning US long-grain rice imports
  • many other countries requiring testing of all imports of U.S. rice

some markets for medium- and short-grain rice being affected

another unapproved Bayer GM rice (LL62) also being detected in U.S. rice supplies

US rice farmers being warned they would never again be able to validly describe their crop as "GM-free".

Tellingly, a key factor in the sale of Aventis CropScience to Bayer was a similar crisis involving GM maize. The Starlink fiasco started when in October 2000 traces of an Aventis GM maize (corn) called StarLink showed up in the food supply in the U.S. even though it only had approval for animal feeds or industrial use. Starlink was not approved for human consumption because the Environmental Protection Agency couldn't rule out the possibility that humans would be allergic to it. The agency's approval had been conditional on Aventis's agreement to keep Starlink from being eaten by humans.

The Starlink fiasco eventually led to a massive recall of over 300 U.S. food brands due to the enormous scale of the contamination. ABC News reported in late November 2000, "In Iowa, StarLink corn represented 1 percent of the total [maize] crop, only 1 percent. It has tainted 50 percent of the harvest.” The ‘StarLink’ gene also showed up unexpectedly in a second company’s maize and in US maize exports. United Press International reported, “Aventis CropScience Wednesday was at a loss to explain why another variety of corn besides its StarLink brand is producing the [StarLink] Cry9C protein." U.S. maize exports to big buyers were badly hurt. Federal officials blamed the unauthorized appearance of geneticially engineered maize in the food supply solely on its manufacturer.

Bayer seems to have a history of  FDA Warnings

The FDA slammed Bayer with two warning letters today for allegedly unlawfully selling two unapproved aspirin products. It is not the first time Bayer's Consumer Health marketers have gone off the rails, raising questions about how professional — or even scientific — the company is when it comes to over-the-counter medicines.

The FDA specifically charged Bayer with wrongfully marketing two aspirin brands, Bayer Women's Low Dose Aspirin + Calcium and Bayer Aspirin With Heart Advantage. The products "are unapproved new drugs that require an approved new drug application in order to be legally marketed," the FDA said

And Now in April 2012, Yaz Is In the News

In late April 2012 Bayer announced that it has settled lawsuits involving YAZ and Yasmin side effects related to blood clots, namely deep vein thrombosis (DVT) and pulmonary embolism (PE) cases.

Young Women Injured By Yaz, Yaz lawyers Helping, Yaz Birth Control Pills Helpline

Written by lisaspitzer on . Posted in Yaz Helpline News

Yaz Lawyers are filing lawsuits Mothers of Daughters Taking Yaz. Yaz has caused  blood clots in young women.

As a young woman reaches the the time in her life when choices must be made about indulging or not the concept of protection becomes important. Yaz birth control pills ere introduced to young women thru Yaz parties as a mean of obtaining sexual freedom. Many found women opted to take birth control pill to have this freedom. Yaz birth control pills were also given out by many Planned Parenthood organizations in minority areas to help young women protect themselves form unwanted pregnancy. At a young age pregnancy usually meant a complete change in life goals. Unwed mothers had many new decisions to make. Many of them found theor careers and goals thwarted by a surprise they were not ready for. Yaz offered the ability to experiment with life and not have to worry about consequences

But there was severe consequences for many women as Yaz began to show signs of complications and many young women were becoming hospitalized with blood clot, stroke, pulmonary embolism and deep vein thrombosis. An unwanted pregnancy can certainly change your life but, a sever disabling illness can have far reaching effects as well.

Many mothers of daughters with complication from Yaz never new theor daughter was taking birth control pills and certainly was not made aware of the potential dangers. To see your daughter have a severe illness at a young age csan be devastating and even more devasting is the possability of facing a loss. Losing a child is one of the most life shattering experiences a mother can go thru. Ones life becomes turned upside down. The anger against these pharmaceutical companies must be over bearing.

Many women have shared stories of strokes due to yaz birth control pills. The reports base the cause of illness on drospirenon. Drospirenon can increase your blood potassium levels (causing hyperkalemia). The elevated level of potassium in the blood may lead to an increased risk of a heart attack. More and more reports from hospital emergency rooms are relating pre mature strokes to birt control pills. Drospirenone in Yaz combined with estrogencan increase the risk of blood clots.

Your body must make blood clots as part of it's normal functioning however the chemical combinations in Yaz can cause abnormal blood clotting. This happens in places where it should not be like a blood vessel, vein or artery. Such abnomal blood clotting casn result in sever complications such as a stroke, pulmonary embolism or deep vein thrombosis. Blood clots can dislodge and move to any part of the body. This can be the brain or lungs. Blood clots in the brain or lungs can be very dangerous and even lead to death. Yaz birth control pills has reportedly put many young women at risk leaving mothers rushing to emergency rooms.

Just recently Bayer has begun settlements on a number of lawsuits for Blood clots, pulmonary embolism and deep vein thrombosis as well as strokes form Yaz. The FDA has demanded an increased warning on Yaz for blood clots.

This is a heavy price to pay for sexual freedom or the option of avoiding an unwanted pregnancy at an inopportune time is one's life. Perhaps it is due to financial constraints,divorce,or the desire for a new career. A life cut short in goals and dreams is a big

Bayer Announces Yaz Settlement, Yaz Birth Control Pills Helpline Launched

Written by lisaspitzer on . Posted in Yaz Helpline News

Bayer Announces yaz Settlement, Yaz Birth Control Pills Helpline Launched

Yaz Helpline announces Bayer Has settled on 500 Yaz lawsuits and the FDA has added additional label warnings for yaz blood clots, stroke and Pulminary embolism. Yaz lawyers are accepting cases for review for yaz.


PRLog (Press Release) – Apr 21, 2012 – Vaginal mesh helpline, Yaz helpline for Women informs that Bayer Pharmaceuticals has annonced a settlement for blood clots form yaz victims. The first round is settling for over $200,000 per claimant. This is good news for all litigations of dangerous drugs and medical devices harming women. Vaginal Mesh helpline has expanded resources to help women injured by other Drugs and Medical devices. With so many drugs and medical devices harming women we see a need for additional helplines. Th Fda Has issued increased warnings on labeling for yaz for strokes, blood clots and pulminary embolism.

The Yaz Helpline sponsored by Vaginal Mesh Helpline and Yaz Lawyers are pleased to announce Bayer, has agreed to pay out at least $110 million to settle 500 lawsuits involving Yaz blood clots. News of the settlements comes at a time when the Yaz lawsuit total exceeds 11,000, with plaintiffs claiming the birth control pill resulted in dangerous Yaz blood clots. The FDA has increased the details of warnings on Yaz labeling to include increased risk of strokes. We can expect justice. Victims of Yaz, It is not too late for you. If you have not filed a claim contact us immediately. yaz can cause wrongful death

Call our new Yaz Birth Control Pills Helpline and  Speak to a female Social Worker and be connected to an experienced Yaz lawyer

The Federal/State Yaz, Yasmin, Ocella Birth Control Lawsuits are being filed by Yaz Lawyers. The Yaz, Yasmine,Ocella Helpline is here to answer your questions and connect you with a YAZ, Yasmin or Ocella lawyer.Referencing the New York Times," Yaz has been one of the top-selling birth control pills in the U.S and Canada., with nearly 20 percent of the market. In 2008, more than $600 million dollars' worth of Yaz was sold in the U.S. However, the television commercials advertising Yaz were of concern to the FDA and the Attorney General because they implied that Yaz could be used to treat or cure symptoms for which it was not FDA-approved, such as:

  • Keeping a woman's mild acne at bay
  • Relieving symptoms of PMS (premenstrual syndrome):
  • irritability
  • increased appetite
  • moodiness
  • fatigue
  • headaches
  • bloating
  • muscle aches

Many Studies show Yaz linked to Blood Clots

two new studies recently published in the British Medical Journal, which concluded that women ages 15-44 taking birth control pills containing the synthetic progestin, drospirenone, are more likely to develop blood clots deep in the veins of the leg (venous thromboembolism), than women using birth control pills containing the common progestin levonorgestrel. The studies reported that the risk of developing blood clots for women taking the drospirenone-containing pills may be two to three times greater than those who take other pills. Yaz is one of these drugs.

Yaz New Warnings April 2012

In an announcement released April 10, 2012, the FDA stated that new warnings about the risk of blood clots will now be required on the labels of birth control pills that contain the progestin “drospirenone.” Yaz, Yasmin, Beyaz, and Safyral will now carry warnings detailing recent studies that suggest these pills may carry a slightly higher risk of Yaz blood clots

Yaz side effects include:

  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE)
  • Blood clots
  • Stroke
  • Heart attack
  • Gallbladder problems
  • Pancreatitis

List of Drugs

Approved Oral Contraceptives containing Drospirenone

Drospirenone and ethinyl estradiol Drospirenone 3 mg and ethinyl estradiol 0.03 mg

Ocella Drospirenone 3 mg and ethinyl estradiol 0.03 mg

Safyral Drospirenone 3 mg, ethinyl estradiol 0.03 mg, and levomefolate calcium 0.451 mg

Syeda Drospirenone 3 mg and ethinyl estradiol 0.03 mg

Yasmin Drospirenone 3 mg and ethinyl estradiol 0.03 mg

Zarah Drospirenone 3 mg and ethinyl estradiol 0.03 mg

Beyaz Drospirenone 3 mg, ethinyl estradiol 0.02 mg and levomefolate calcium 0.451 mg

Drospirenone and ethinyl estradiol Drospirenone 3 mg and ethinyl estradiol 0.02 mg

Gianvi Drospirenone 3 mg and ethinyl estradiol 0.02 mg

Loryna Drospirenone 3 mg and ethinyl estradiol 0.02 mg

Yaz Drospirenone 3 mg and ethinyl estradiol 0.02 mg

Recent warnings have linked various birth control drugs and devices to serious injuries and even death:

  • Yasmin®
  • Yaz®
  • Ocella®

Injuries reported:

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Stroke
  • Heart Attack
  • Wrongful Death
  • Blood Clot Related Injuries
  • Kidney Failure
  • Gallbladder Injury/Removal

If you or a loved one has suffered from any of the harmful side effects of Yaz,Yasmin or Ocella such as blood clots, stroke or heart attack you may be entitled to file a Yaz,Yasmin,Ocella lawsuit against the manufacturer. Call us for a yaz lawyer with experience in birth control drug lawsuits toevaluate your claim. Many women around the United States have suffered from life-threatening Yaz,Ocella and Yasmin birth control side effects. The manufacturer can be held liable.

The Woman's Yaz Birth Control Pills Helpline is here for women suffering from Yaz and Drospirenone side effects

Yaz Birth Control Pill helpline Announces Bayer Said to pay $110 Million, Yaz lawyers Ready

Written by lisaspitzer on . Posted in Yaz Helpline News

Yaz birth control pills have harmed many women by causing blood clots, Pulmonary Embolism, Stroke and heart Attacks. Yaz Birth Control pill helpline is happy to announce that Bayer Said to Pay $110 Million in Yaz Birth-Control Cases

By Jef Feeley and Margaret Cronin Fisk – Apr 13, 2012 5:48 PM ET

Bayer Germany’s largest drugmaker, will pay at least $110 million to settle about 500 lawsuits over claims that its Yasmin line of birth-control pills caused blood clots, in the first resolution of cases over the product, people familiar with the agreements said.

Officials of Bayer, based in Leverkusen, Germany, agreed to pay an average of about $220,000 a case to resolve the claims that its Yasmin and Yaz contraceptives caused sometimes fatal clots that can lead to heart attacks and strokes, two people familiar with the settlement said. The people sought anonymity because the accords haven’t been made public.

Bayer fell 2.5 percent in German trading today, and its American depositary receipts dropped 3.8 percent. The settlements came after a federal judge in Illinois postponed a Jan. 9 trial of a suit accusing Bayer and some of its units of misleading women about the health risks of its birth-control pills so a mediator could try to negotiate a settlement.

The case was the first set for trial of more than 11,000 lawsuits over injuries allegedly caused by the drugs.

“Sounds to me like mediation is paying off,” Carl Tobias, who teaches product-liability law at the University of Richmond in Virginia, said in a phone interview. “As a German company, Bayer probably would like to avoid the risks and costs of litigation in U.S. courts. Mediation tends to be a less- expensive way to deal with these kinds of cases.”

Stronger Warnings

The settlements come as the U.S. Food and Drug Administration April 10 ordered Bayer and other contraceptive makers to strengthen the blood-clot warnings on their products.

Pills like Bayer’s Yasmin, which contain a synthetic hormone called drospirenone, will have warning labels saying researchers have found they may triple the risk for clots.

Bayer’s contraceptives generated $1.58 billion in sales in 2010, making them the drugmaker’s biggest-selling drugs after Betaseron, a multiple sclerosis medication. The Yasmin drugs have been the focus of regulators who question their safety.

“Bayer HealthCare confirms that some cases pending in the current YAZ/Yasmin litigation in the U.S. are being settled,” Rosemarie Yancosek, a U.S. spokeswoman for the drugmaker, said in an e-mailed statement. She declined to comment on the number of cases settled or the amount of the accords.

Bayer’s American depository receipts, each worth one ordinary share, fell $2.60, or 3.8 percent, to $65.83 in over- the counter trading today. Shares in Germany dropped 1.28 euros, or 2.5 percent, to 50.56 euros.

Prior Settlements

Bayer officials said in a Feb. 28 U.S. Securities and Exchange Commission filing that the drugmaker has settled 70 cases over the Yasmin line of contraceptives.

Those settlements included “terms and conditions which Bayer views to be reasonable,” officials said in the filing. “Bayer will continue to consider the option of settling individual lawsuits in the U.S. on a case-by-case basis.”

The company is expecting additional suits, officials said in the SEC filing. Last year, the U.S. Food and Drug Administration warned that women taking the pills were 74 percent more likely to suffer blood clots than women on other low-estrogen contraceptives.

The FDA examined data on more than 835,000 women who took pills containing drospirenone, including Bayer’s Yasmin line of birth-control pills, according to the FDA report.

Bayer’s Yasmin was the No. 4 oral contraceptive in the U.S. in 2011, with 4.6 percent of the market as of September, according to data from IMS Health.

Wave of Litigation

Since 2009, the German drugmaker has faced a wave of lawsuits in courts across the U.S. alleging the birth-control pills caused sometimes fatal blood clots. Lawyers suing the drugmaker cited FDA reports of at least 50 deaths tied to the pills from 2004 to 2008.

Lawyers for former Yaz users contend in court filings that Bayer officials sought to market the contraceptive fgor unapproved uses and misled women about the drug’s health risks

The cases filed in federal courts were consolidated before U.S. District Judge David Herndon in East St. Louis, Illinois, for pretrial proceedings.

Scheduled Trials

Herndon scheduled a series of trials for early this year so juries could begin weighing claims that Bayer and its units marketed Yaz and other contraceptives as safer than rivals’ products while knowing they posed a higher clot risk.

At Bayer’s suggestion, Herndon called in Stephen Saltzburg, a George Washington University law professor, to serve as a mediator. Saltzburg’s job was to explore the possibility of “settlements in this litigation,” Herndon said in a December 2011 order. The judge put the trial schedule on hold while Saltzburg met with lawyers for the drugmakers and former Yaz users.

Among the lawyers settling Yaz cases as a result of Saltzburg’s efforts are mark Robinson, Chris Seeger and Michael Berg the people familiar with the accords said.

Those three lawyers are serving on the so-called plaintiffs steering committee in the cases before Herndon, according to court filings That group helps decide how the consolidated cases should progress through the litigation process.

Burg, a Denver-based plaintiffs’ lawyer who handles product-liability cases, also is listed in court filings as co- lead plaintiffs’ counsel in the Yaz cases. He declined to comment on the settlements in a interview today.

Seeger, based in New York, and Robinson, a Los Angeles- based attorney, didn’t immediately return calls seeking comment on the settlement.

The case is In re Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Product Liability Litigation, 09-md-02100, U.S. District Court, Southern District of Illinois (East St. Louis).

Margaret Cronin Fisk

editor responsible for this story: Michael Hytha

If you have been severly injured by Yaz or Yasmin or a loved one died contact us immediately to see if you are eligible to be a part of this lawsuit .

FDA Reviewed Risks Of yaz, Yaz Birth control Pills Helpline

Written by lisaspitzer on . Posted in Yaz Helpline News

Yaz lawsuits mounting up. Bayer began settlements for Yaz. Contact a yaz Blood Clot lawyer today. File your Yaz lawsuit.                                               The Yaz Men: Members of FDA panel reviewing the risks of popular Bayer contraceptive had industry ties

By Jeanne Lenzer and Keith Epstein

Facebook Twitter Digg Reddit StumbleUpon Delicious

Last month, the U.S. Food and Drug Administration convened a committee of medical experts to weigh new evidence concerning the potential dangers of drospirenone, a synthetic hormone contained in popular birth control pills including Bayer AG’s Yaz and Yasmin. In a decision that helped ensure the continued presence of these drugs on American pharmacy shelves, the committee concluded by a four-vote margin that the benefits of drugs with drospirenone outweigh the risks. However, an investigation by the Washington Monthly and the British medical journal BMJ has found that at least four members of the committee have either done work for the drugs’ manufacturers or licensees or received research funding from them. The FDA made none of those financial ties public.

Yaz and Yasmin are among Bayer’s top selling pharmaceutical products. According to the German drug manufacturer, over 4 million women worldwide use Yasmin alone. But the drug has also sparked growing controversy in recent months. A series of studies published in BMJ have shown that users of pills containing drospirenone have an increased risk of blood clots, which can cause deep vein thrombosis, pulmonary embolism, stroke, heart attack and death. And thousands of women have filed a lawsuit against Bayer, saying they were injured by Yaz or Yasmin.

Other Bayer products containing the hormone drospirenone are Beyaz and Safyral. In addition, four companies—Bayer, Teva, Watson and Sandoz—sell five generic versions of the drugs evaluated by the committee last month.

The FDA’s decision not to reveal its advisors’ relationships with the drugs’ manufacturers and Bayer raises serious questions about the agency’s treatment of potential conflicts of interest, a historically problematic area for the department. In 2004, controversy erupted over another FDA advisory hearing—involving the painkiller Vioxx—when it became clear that advisors with financial conflicts of interest were more likely than those without conflicts to vote that Vioxx was safe and should be allowed to stay on the market. The drug was ultimately withdrawn after a study showed it was associated with approximately 60,000 deaths. In 2008, partly in response to this uproar, the agency issued a new guidance on how to handle conflicts of interest among its advisors, stating that it wanted to reduce “bias” and to be more “transparent.”

The agency’s handling of the drospirenone hearings casts major doubt on how far it has gone to attain those goals.

What’s more, interviews and records also show that the drospirenone advisory committee, when it voted last month, lacked significant information about increased risks to the health of women using contraceptives containing drospirenone.

The FDA ordered the safety review of drugs containing the hormone after three articles published in the BMJ found an increased incidence of blood clots among users of the pills. The advisors were given these studies prior to the December 8 meeting. However, the panel was not shown documents from a report by David Kessler, a former FDA commissioner and an expert witness in the lawsuit filed against Bayer on behalf the women who say they were injured by Yaz and Yasmin. Kessler’s report cites internal Bayer corporate documents that suggest the company had withheld safety data from the FDA.

The documents show that in 2004, Bayer scientists reported in a draft analysis that Yasmin incurs a “several-fold increase” in reporting rates for blood clots compared to three other oral contraceptives, and that Yasmin’s rate of all serious adverse events was “10 fold higher” than that of other products.

In his report, Kessler writes that Bayer failed to report safety data to the FDA, engaged in off-label promotion of the pills, and paid $450,000 to a high profile gynecologist to sponsor her book tour in which she promoted such off-label uses.

Kessler’s report, originally under seal, was not released until December 6, two days prior to the advisory meeting. The FDA said it could not give the advisors the information because the date to submit documents had passed.


The FDA relies on some 50 advisory committees to obtain “independent” expert advice and “maintain the public trust.” Recommendations on evidence for safety and efficacy can lead to drug approvals and withdrawals; while nonbinding, recommendations by such committees can move stock prices and are generally regarded as indicators of official FDA action.

Under FDA guidelines, when advisory committee members have a financial relationship with a drug company whose product is under review, the agency can issue waivers that acknowledge the advisors’ links to industry but allow them to vote if their expertise is needed and no other specialists are available. Such waivers often serve as the only public signal that advisors have financial conflicts of interest. In the hearings on drospirenone, the FDA issued none.

And yet, according to public records, recently unsealed court documents, and interviews with some of the FDA advisors, at least four of the advisory committee members in this case have served as paid researchers, consultants, “key opinion leaders,” or speakers for Bayer or other manufacturers or licensees of drospirenone. A fifth advisor agreed to serve as a consultant but never executed the agreement. A sixth received consulting fees from a law firm representing Bayer.

In a 15-to-11 vote, the committee decided that the benefits of drospirenone outweighed its risks.Had those members with undisclosed conflicts of interest voted the other way, the committee would have come to the opposite conclusion. The committee also voted 21 to 5 to change the drug labels to warn that the hormone can cause blood clots. But the panel stopped short of recommending that the labels should warn that they are more likely than other contraceptive pills to cause blood clots. Instead the experts suggested that the labels say that the evidence about blood clots is “conflicting.”

Ironically, while the FDA allowed voting by advisors with business connections to drospirenone, the agency did bar another advisor—Sidney M. Wolfe, the panel’s lone consumer advocate—on the grounds that he has an “intellectual conflict of interest.” Wolfe, a former researcher, is a frequent critic of FDA practices on behalf of the advocacy group Public Citizen. Wolfe, the author of the consumer guide Good Pills, Bad Pills, had marked Yaz with a “do not take” advisory to readers. Jerome Hoffman, professor emeritus of medicine at UCLA, questioned Wolfe’s exclusion from the panel: “The idea that because he has an opinion on data that already exist he should be prevented from voting is nutty.”

Each of the advisors with ties to manufacturers told the Washington Monthly and BMJ that they fully disclosed their ties to the FDA, and there are no indications that the advisors failed to make required disclosures to the agency. The FDA, however, has declined to make public advisors’ financial conflict of interest forms, explaining that the forms are “confidential” and no information from them can be shared under a section of the Ethics in Government Act.

When asked whether the agency was aware of any financial ties between its advisors and manufacturers or distributors of drospirenone, FDA spokeswoman Morgan Liscinsky said, “No waivers were issued.”

But the committee’s financial ties to Bayer begin with no less than its acting chair. Julia Johnson, a professor of obstetrics and gynecology at the University of Massachusetts Medical School, conducted four clinical trials—including one of drospirenone as hormone replacement—for Bayer or its subsidiary Berlex, a manufacturer of drospirenone. She said in an e-mail, “The FDA is very vigilant on examining potential conflicts of interest and was aware of all my research.” When asked for an interview, she said, “The U.S. FDA states that I cannot speak about the meeting.”

Another advisor with ties to industry is Paula Hillard, a professor of obstetrics and gynecology at Stanford School of Medicine who has served as a paid consultant to Bayer Schering. Dr Hillard said she had fully complied with all FDA disclosures and referred the Washington Monthly and BMJ to the FDA for further questions. The FDA declined to respond to any questions, again citing the confidentiality clause of the Ethics in Government Act.

Elizabeth Raymond, a senior medical associate at Gynuity Health Projects in New York and another member of the committee, conducted studies funded by Barr, which has a licensing agreement with Bayer for generic versions of Yaz. Dr Raymond said that the FDA was “fully aware of all of my relevant current and past activities.”

Anne E. Burke, an assistant professor of gynecology and obstetrics at Johns Hopkins University in Baltimore, has received research funding from Bayer-Berlex and Duramed, which has a licensing agreement with Bayer for generic Yaz and Yasmin. Dr Burke said that she fully disclosed this to the agency.

According to Dr Kessler’s report, an internal Bayer document indicated that a fifth advisor received payment from Bayer, but that advisor told the Washington Monthly and BMJ that although she initially agreed to serve as a consultant for Bayer, the company never pursued the agreement. She said FDA records indicated that she had ties to Bayer due to her disclosure about her agreement, but after she was nominated to be on the drospirenone advisory committee, she corrected the error.

A sixth advisor, meanwhile, confirmed that he received consulting fees from a law firm representing Bayer in 2006. He told BMJ and the Washington Monthly that he did not disclose the information to the FDA because the FDA “did not require information for that time frame for consulting unrelated to the meeting topic.”

Bayer spokesperson, Rosemarie Yancosek, said in an e-mailed statement: “Bayer had no input on who serves on the U.S. FDA Advisory Committee panel as the FDA has its own process for selecting panel members. Furthermore, it is Bayer’s understanding that the FDA has a procedure for determining conflicts of interest for potential panel members.”

The FDA does indeed have such a procedure, but critics argue that its guidelines define conflicts of interest too narrowly and provide too much flexibility in how they are applied. The guidelines are technically “suggested or recommended, but not required” provisions (http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM125646.pdf). Whether an advisor can participate depends on “whether the discussion at the meeting or outcomes of the meeting will have a direct and predictable effect on the individual’s interest.” For instance, someone who was previously involved in another role for a manufacturer, or whose university received money from a manufacturer, may be allowed to participate. Even having a contract for $100,000 over a five-year period would not necessarily exclude an advisor, according to the guidelines.

Despite the FDA’s frequent claims that there aren’t enough experts independent of industry, a list of over 100 industry-independent experts has been presented to the agency – yet none of those experts has been tapped as an advisor.

The Project on Government Oversight, a Washington-based nonpartisan watchdog group, plans to raise concerns about the FDA’s conflict of interest policies in a letter to the agency’s top official, Margaret Hamburg.

“It shouldn’t require a lawsuit and investigative journalism to learn about these kinds of conflicts,” said the group’s executive director, Danielle Brian. “The Yaz case puts FDA’s feckless ethics policy into stark relief. It also reveals the human impact of conflicts of interest and why we need an FDA that shuns even the appearance of such conflicts.”

The organization intends to urge the FDA to routinely disclose industry ties and more aggressively determine whether an advisor has a conflict. “Right now,” said Brian, “the bar for considering whether an advisor has a conflict is too high.”

Jeanne Lenzer and Keith Epstein collaborated on this article. Lenzer is a medical investigative journalist based in New York. Epstein is a Washington-based investigative editor and writer.